导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.42% | 3056/4773 |
| 近一周 | -1.33% | 2037/5465 |
| 近一月 | -1.27% | 1089/5421 |
| 近一季 | 0.22% | 961/5231 |
| 近半年 | -0.50% | 1495/4920 |
| 近一年 | 1.73% | 2424/4394 |
| 近两年 | 40.35% | 1885/2954 |
| 近三年 | 26.29% | 1251/2253 |
| 成立以来 | 46.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.15% 4046/4961 |
7.11% 2748/5312 |
- - |
- - |
| 2025 | 17.52% 2375/4813 |
-0.25% 2144/3635 |
2.93% 1260/4076 |
11.41% 3167/4524 |
2.74% 866/4813 |
| 2024 | 18.79% 575/3463 |
3.47% 561/2808 |
-0.13% 688/3014 |
17.24% 1227/3129 |
-1.95% 1899/3463 |
| 2023 | -8.45% 1017/2656 |
1.13% 1640/2280 |
-4.40% 1163/2385 |
1.82% 273/2515 |
-6.99% 2007/2655 |
| 2022 | -17.11% 551/2207 |
-11.45% 513/1919 |
6.73% 620/2016 |
-13.57% 922/2113 |
1.46% 1257/2208 |
| 2021 | -7.96% 1043/1822 |
-2.83% 712/1255 |
-0.29% 1138/1330 |
-7.30% 1042/1466 |
2.48% 579/1822 |
| 2020 | 19.87% 727/1250 |
-12.31% 882/1028 |
10.35% 772/1067 |
10.41% 555/1164 |
12.20% 492/1184 |
| 2019 | 29.27% 509/1092 |
17.73% 651/754 |
4.30% 31/804 |
-0.08% 575/850 |
5.36% 729/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银瑞信上证50ETF VS. 长安沪深300非周期A(740101) |